Amarin, Ariad, Vical, Dendreon and Aveo. You get to decide which CEO deserves to wear the badge of shame.
Bob Hugin of Celgene tops a highly qualified field of nominees to win this year's Best Biotech CEO award.
Gilead's decision to price Sovaldi at $84,000 per treatment may open door for competitors like Abbvie to gain market share from cost-conscious pharmacy benefits managers.
Imetelstat may be the first drug to affect underlying cause of myelofibrosis but more data are needed to confirm its benefit.
The new hepatitis C pill is expected to shatter drug launch records with $2 billion in sales in its first year.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
The CEOs from NPS Pharma, Onyx Pharma, Bristol-Myers Squibb, Celgene and Ligand Pharma vie for the coveted title of Best Biotech CEO.
Leukemia and Lymphoma Society has asked Stemline to stop using cancer patient testimonials in its investor presentations.
The cash will paid to top execs if Amarin can win an expansion of its fish-oil pill.
After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.